Joint Crisis Plan Effectiveness in Preventing Relapses in Schizophrenia and Schizoaffective Disorder

Overview

The Joint Crisis Plan = SOS Plan is a reference to a particular form of psychiatric advance directive which involves the patient, the healthcare team, their relatives and a third party caregiver as intermediary for the project. The main objective is to evaluate the effectiveness of the SOS Plan (JCP) in terms of the reduction in hospitalisations within 18 months of its development by comparison to the standard psychiatric care. Thus, the investigators' proposal is that SOS Plan's are regularly reassessed every 6 months and again where there is an unplanned psychiatric readmission that lasts beyond two weeks. Single blind multicentre randomised trial with parallel control groups. Effectiveness study of a psychiatric care strategy.

Full Title of Study: “Effectiveness of a Joint Crisis Plan (SOS Plan) in Preventing Relapses in Patients Diagnosed With Schizophrenia and Schizoaffective Disorder”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Prevention
    • Masking: Single (Outcomes Assessor)
  • Study Primary Completion Date: January 2022

Detailed Description

Single blind multicentre randomised trial with parallel control groups. 2 groups: – SOS Intervention Group: benefits from the SOS Plan in addition to the usual follow-ups – "Control" Group: receive no additional intervention (only receive the routine follow-ups) OBJECTIVES : – To evaluate the effectiveness of the SOS Plan (JCP) in terms of the reduction in hospitalisations within 18 months of its development by comparison to the standard psychiatric care – To evaluate : 1. the cumulative length of hospitalisations (in days) in the two years following the development of the SOS plan 2. the type of hospitalisation (voluntary or compulsory) 3. the number of hospitalisations for a given subject 4. the number of crisis situations that may require the use of the SOS Plan 5. the clinical condition of the patient 6. the patient with the most responses to the SOS Plan in socio-demographic terms 7. the patient satisfaction in using the SOS Plan 8. the decisional autonomy during treatment 9. the quality of the therapeutic alliance 10. the length of the meeting to develop the SOS Plan 11. the quality of life 12. the medico-economic impact EXECUTION OF PRACTICAL RESEARCH : 1. The inclusion visit will be completed apart from a period of acute psychiatric decompensation, while the patient is capable of consenting to treatment. The inclusion visit will be completed within a hospital department before the patient is finally released from hospitalisation or during an outpatient follow-up. This involves placing the patient on the Positive And Negative Syndrome Scale (PANSS) to ensure that the patient's clinical condition allows him to consent to treatment. A score above 95 excludes the patient. The investigator also outlines the study and schedules visits. The patient then signs both the information letter and informed consent. A urine pregnancy test will be carried out on women of childbearing age. 2. Randomisation will be performed by a member of the SOS regional-referral team. For patients in the SOS Intervention group: – Preparatory interview with an SOS regional referrer – SOS Plan development meeting in the presence of the patient, the treating psychiatrist, one or more relatives, and an SOS regional referrer For patients in the control group: tracking the continuation of psychiatric care according to the standard care terms 3 ) Follow-up visits: for the two groups: 4 visits M6, M12, M18, M24 At each visit: meeting with an independent regional SOS assessor blind to allocation. For both of the groups: – Assessment of the clinical condition: placement on the PANSS scale – Number of psychiatric hospitalisations, types of hospitalisation, duration of hospitalisation since the last visit – Satisfaction assessment (numeric scale), of the therapeutic alliance (WAI), of decision-making autonomy (API), of quality of life (SF-36) For the SOS Intervention group: – Updating the SOS Plan after each relapse that leads to an unscheduled psychiatric hospitalisation lasting more than two weeks. – Updating the SOS Plan every 6 months in the absence of hospitalisation

Interventions

  • Procedure: SOS Plan
    • It is a customised procedure that involves a meeting (crisis planning meeting) with the patient, their various medical and social referrers and any other person who they may have desired to invite. The booklet outlines four avenues to consider: Contact details / contact person Treatment and current follow-ups Medical care in the event of a crisis Practical aid in the event of a crisis Updating the SOS Plan every 6 months in the absence of hospitalisation or after each relapse that leads to an unscheduled psychiatric hospitalisation lasting more than two weeks.

Arms, Groups and Cohorts

  • Experimental: SOS Intervention Group
    • Subjects benefit from the SOS Plan in addition to the usual follow-ups
  • No Intervention: Control Group
    • Subjects receive no additional intervention (tracking the continuation of psychiatric care according to the standard care terms)

Clinical Trial Outcome Measures

Primary Measures

  • incidence of the first psychiatric hospitalisation
    • Time Frame: 18 months
    • the incidence of the first psychiatric hospitalisation within 18 months following inclusion

Secondary Measures

  • cumulative time in days of psychiatric hospitalisations
    • Time Frame: 2 years
    • the cumulative time, in days, of psychiatric hospitalisations in the two years following inclusion
  • types of psychiatric hospitalisations
    • Time Frame: 2 years
    • the types of psychiatric hospitalisation: voluntary (SL) or compulsory (SDT)
  • number of hospitalisations
    • Time Frame: 2 years
    • the number of hospitalisations for each subject
  • number of emergency psychiatric consultations
    • Time Frame: 2 years
    • the number of emergency psychiatric consultations
  • clinical assessment by the PANSS scale
    • Time Frame: every 6 months during 2 years
    • PANSS score (intensity and qualitative aspects of the clinical situation)
  • patient satisfaction
    • Time Frame: every 6 months during 2 years
    • score at a numeric scale of patient satisfaction
  • Autonomy Preference Index
    • Time Frame: every 6 months during 2 years
    • decision making-autonomy assessment
  • Working Alliance Inventory
    • Time Frame: every 6 months during 2 years
    • the working alliance assessment
  • length of the meeting to develop the SOS Plan
    • Time Frame: every 6 months during 2 years
    • the length of the meeting to develop the SOS Plan in minutes
  • SF-36 quality of life
    • Time Frame: every 6 months during 2 years
    • quality of life assessment by the SF-36
  • medical cost
    • Time Frame: every 6 months during 2 years
    • numbers of hospitalisations, of consultations, drugs consummation

Participating in This Clinical Trial

Inclusion Criteria

  • Aged between 18 and 65 years – Diagnosed with schizophrenia or schizoaffective disorder according to criteria specified in DSM – Psychiatric inpatient or an outpatient with a specialised framework of psychiatric follow-ups – Patient has been hospitalised at least once in a psychiatric department within the previous 2 years – Adults under protective measures can be included (guardianship/supervision). Consent will also be sought from the guardian or trusted person. – Registered for social security Exclusion Criteria:

  • Refusal to participate in the study – Unable to give his or her written consent – Patients detained – Pregnant or lactating women

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 65 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • University Hospital, Lille
  • Collaborator
    • Ministry of Health, France
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Guillaume Vaiva, Principal Investigator, University Hospiltal Lille
  • Overall Contact(s)
    • Elsa MAITRE, 1.45.65.61.21, e.maitre@ch-sainte-anne.fr

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.